Guided Therapeutics (OTCMKTS:GTHP – Get Free Report) is one of 74 publicly-traded companies in the “Electromedical equipment” industry, but how does it compare to its rivals? We will compare Guided Therapeutics to related businesses based on the strength of its risk, dividends, earnings, institutional ownership, profitability, valuation and analyst recommendations.
Earnings and Valuation
This table compares Guided Therapeutics and its rivals gross revenue, earnings per share and valuation.
Gross Revenue | Net Income | Price/Earnings Ratio | |
Guided Therapeutics | $100,000.00 | -$3.49 million | -5.83 |
Guided Therapeutics Competitors | $1.04 billion | $89.46 million | -7.33 |
Guided Therapeutics’ rivals have higher revenue and earnings than Guided Therapeutics. Guided Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Analyst Ratings
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Guided Therapeutics | 0 | 0 | 0 | 0 | N/A |
Guided Therapeutics Competitors | 269 | 802 | 2008 | 109 | 2.61 |
As a group, “Electromedical equipment” companies have a potential upside of 3,139.56%. Given Guided Therapeutics’ rivals higher probable upside, analysts plainly believe Guided Therapeutics has less favorable growth aspects than its rivals.
Insider & Institutional Ownership
9.7% of Guided Therapeutics shares are owned by institutional investors. Comparatively, 44.1% of shares of all “Electromedical equipment” companies are owned by institutional investors. 66.8% of Guided Therapeutics shares are owned by insiders. Comparatively, 14.5% of shares of all “Electromedical equipment” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Profitability
This table compares Guided Therapeutics and its rivals’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Guided Therapeutics | N/A | N/A | -138.23% |
Guided Therapeutics Competitors | -331.29% | -92.21% | -30.02% |
Risk and Volatility
Guided Therapeutics has a beta of 0.52, suggesting that its share price is 48% less volatile than the S&P 500. Comparatively, Guided Therapeutics’ rivals have a beta of 17.29, suggesting that their average share price is 1,629% more volatile than the S&P 500.
Summary
Guided Therapeutics rivals beat Guided Therapeutics on 6 of the 10 factors compared.
About Guided Therapeutics
Guided Therapeutics, Inc., a medical technology company, focuses on developing medical devices. It focuses on the commercialization of LuViva, a non-invasive cervical cancer detection device that identifies cervical cancers and precancers painlessly, non-invasively, and at the point-of-care by scanning the cervix with light, then analyzing the light reflected and fluorescent light. The company was formerly known as SpectRx, Inc. and changed its name to Guided Therapeutics, Inc. in February 2008. Guided Therapeutics, Inc. was incorporated in 1992 and is based in Norcross, Georgia.
Receive News & Ratings for Guided Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guided Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.